<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alloza, E.</style></author><author><style face="normal" font="default" size="100%">Fatima Al-Shahrour</style></author><author><style face="normal" font="default" size="100%">Cigudosa, J. C.</style></author><author><style face="normal" font="default" size="100%">Dopazo, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A large scale survey reveals that chromosomal copy-number alterations significantly affect gene modules involved in cancer initiation and progression</style></title><secondary-title><style face="normal" font="default" size="100%">BMC Medical Genomics</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">06/05/2011</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.biomedcentral.com/1755-8794/4/37</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">4</style></volume><pages><style face="normal" font="default" size="100%">37</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;h4&gt;Background&lt;/h4&gt; &lt;p&gt;Recent observations point towards the existence of a large number of neighborhoods composed of functionally-related gene modules that lie together in the genome. This local component in the distribution of the functionality across chromosomes is probably affecting the own chromosomal architecture by limiting the possibilities in which genes can be arranged and distributed across the genome. As a direct consequence of this fact it is therefore presumable that diseases such as cancer, harboring DNA copy number alterations (CNAs), will have a symptomatology strongly dependent on modules of functionally-related genes rather than on a unique &amp;quot;important&amp;quot; gene.&lt;/p&gt; &lt;h4&gt;Methods&lt;/h4&gt; &lt;p&gt;We carried out a systematic analysis of more than 140,000 observations of CNAs in cancers and searched by enrichments in gene functional modules associated to high frequencies of loss or gains.&lt;/p&gt; &lt;h4&gt;Results&lt;/h4&gt; &lt;p&gt;The analysis of CNAs in cancers clearly demonstrates the existence of a significant pattern of loss of gene modules functionally related to cancer initiation and progression along with the amplification of modules of genes related to unspecific defense against xenobiotics (probably chemotherapeutical agents). With the extension of this analysis to an Array-CGH dataset (glioblastomas) from The Cancer Genome Atlas we demonstrate the validity of this approach to investigate the functional impact of CNAs.&lt;/p&gt; &lt;h4&gt;Conclusions&lt;/h4&gt; &lt;p&gt;The presented results indicate promising clinical and therapeutic implications. Our findings also directly point out to the necessity of adopting a function-centric, rather a gene-centric, view in the understanding of phenotypes or diseases harboring CNAs.&lt;/p&gt;</style></abstract><work-type><style face="normal" font="default" size="100%">Research article</style></work-type></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Largo, C.</style></author><author><style face="normal" font="default" size="100%">Alvarez, S.</style></author><author><style face="normal" font="default" size="100%">Saez, B.</style></author><author><style face="normal" font="default" size="100%">Blesa, D.</style></author><author><style face="normal" font="default" size="100%">Martin-Subero, J. I.</style></author><author><style face="normal" font="default" size="100%">Gonzalez-Garcia, I.</style></author><author><style face="normal" font="default" size="100%">Brieva, J. A.</style></author><author><style face="normal" font="default" size="100%">Dopazo, J.</style></author><author><style face="normal" font="default" size="100%">Siebert, R.</style></author><author><style face="normal" font="default" size="100%">Calasanz, M. J.</style></author><author><style face="normal" font="default" size="100%">Cigudosa, J. C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Identification of overexpressed genes in frequently gained/amplified chromosome regions in multiple myeloma</style></title><secondary-title><style face="normal" font="default" size="100%">Haematologica</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">B-Cell</style></keyword><keyword><style  face="normal" font="default" size="100%">Caspases Cell Line</style></keyword><keyword><style  face="normal" font="default" size="100%">Human *Gene Amplification Gene Dosage Gene Expression Profiling *Gene Expression Regulation</style></keyword><keyword><style  face="normal" font="default" size="100%">Marginal Zone/genetics Multiple Myeloma/*genetics Neoplasm Proteins/genetics Proto-Oncogene Proteins c-bcl-2/genetics</style></keyword><keyword><style  face="normal" font="default" size="100%">Neoplasm Humans Immunoglobulin Heavy Chains/genetics Lymphoma</style></keyword><keyword><style  face="normal" font="default" size="100%">Neoplastic Gene Rearrangement *Genes</style></keyword><keyword><style  face="normal" font="default" size="100%">Tumor *Chromosomes</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2006</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=16461302</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">2</style></number><volume><style face="normal" font="default" size="100%">91</style></volume><pages><style face="normal" font="default" size="100%">184-91</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">BACKGROUND AND OBJECTIVES: Multiple myeloma (MM) is a malignancy characterized by clonal expansion of plasma cells. In 50% of the cases, the neoplastic transformation begins with a chromosomal translocation that juxtaposes the IGH gene locus to an oncogene. Gene copy number changes are also frequent in MM but less characterized than in other neoplasias. We aimed to characterize genes that are amplified and overexpressed in human myeloma cell lines (HMCL) to provide putative molecular targets for MM therapy. DESIGN AND METHODS: Nine HMCL were characterized by fluorescent in situ hybridization, comparative genomic hybridization (CGH) and cDNA microarrays for gene expression profiling and copy number changes. RESULTS: After defining the IGH-translocations present in the cell lines, we conducted expression-profiling analysis. Supervised analysis identified 166 genes with significantly different expression among the cell lines harboring MMSET/FGFR3 (4p16), MAF (16q) and CCND1 (11q13) rearrangements. Array-CGH was then performed. Five chromosomes recurrently affected by gains/amplifications in primary samples and cell lines were analyzed in detail. Sixty amplified and overexpressed genes were found and 25 (42%) of them were only overexpressed when amplified; moreover, six showed a significant association between overexpression and gain/amplification. We also found co-amplification and overexpression for genes located within the same amplicons, such as MALT1 and BCL2. INTERPRETATION AND CONCLUSIONS: Parallel analysis of gene copy numbers and expression levels by cDNA microarray in MM allowed efficient identification of genes whose expression levels are elevated because of increased copy number. This is the first time that MALT1 and BCL2 have been shown to be overexpressed and amplified in MM.</style></abstract><notes><style face="normal" font="default" size="100%">Largo, Cristina Alvarez, Sara Saez, Borja Blesa, David Martin-Subero, Jose I Gonzalez-Garcia, Ines Brieva, Jose A Dopazo, Joaquin Siebert, Reiner Calasanz, Maria J Cigudosa, Juan C Research Support, Non-U.S. Gov’t Italy Haematologica Haematologica. 2006 Feb;91(2):184-91.</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hoffmann, R.</style></author><author><style face="normal" font="default" size="100%">Dopazo, J.</style></author><author><style face="normal" font="default" size="100%">Cigudosa, J. C.</style></author><author><style face="normal" font="default" size="100%">Valencia, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">HCAD, closing the gap between breakpoints and genes</style></title><secondary-title><style face="normal" font="default" size="100%">Nucleic Acids Res</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">*Chromosome Breakage Chromosome Disorders/diagnosis/*genetics *Databases</style></keyword><keyword><style  face="normal" font="default" size="100%">Genetic Genes *Genetic Predisposition to Disease Humans PubMed Systems Integration</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2005</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=15608250</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">Database issue</style></number><volume><style face="normal" font="default" size="100%">33</style></volume><pages><style face="normal" font="default" size="100%">D511-3</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Recurrent chromosome aberrations are an important resource when associating human pathologies to specific genes. However, for technical reasons a large number of chromosome breakpoints are defined only at the level of cytobands and many of the genes involved remain unidentified. We developed a web-based information system that mines the scientific literature and generates textual and comprehensive information on all human breakpoints. We show that the statistical analysis of this textual information and its combination with genomic data can identify genes directly involved in DNA rearrangements. The Human Chromosome Aberration Database (HCAD) is publicly accessible at http://www.pdg.cnb.uam.es/UniPub/HCAD/.</style></abstract><notes><style face="normal" font="default" size="100%">Hoffmann, Robert Dopazo, Joaquin Cigudosa, Juan C Valencia, Alfonso Research Support, Non-U.S. Gov’t England Nucleic acids research Nucleic Acids Res. 2005 Jan 1;33(Database issue):D511-3.</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cascon, A.</style></author><author><style face="normal" font="default" size="100%">Ruiz-Llorente, S.</style></author><author><style face="normal" font="default" size="100%">Rodriguez-Perales, S.</style></author><author><style face="normal" font="default" size="100%">Honrado, E.</style></author><author><style face="normal" font="default" size="100%">Martinez-Ramirez, A.</style></author><author><style face="normal" font="default" size="100%">Leton, R.</style></author><author><style face="normal" font="default" size="100%">Montero-Conde, C.</style></author><author><style face="normal" font="default" size="100%">Benitez, J.</style></author><author><style face="normal" font="default" size="100%">Dopazo, J.</style></author><author><style face="normal" font="default" size="100%">Cigudosa, J. C.</style></author><author><style face="normal" font="default" size="100%">M. Robledo</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A novel candidate region linked to development of both pheochromocytoma and head/neck paraganglioma</style></title><secondary-title><style face="normal" font="default" size="100%">Genes Chromosomes Cancer</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">80 and over Child Chromosomes</style></keyword><keyword><style  face="normal" font="default" size="100%">Adolescent Adrenal Gland Neoplasms/*genetics Adult Aged Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Biological/*genetics</style></keyword><keyword><style  face="normal" font="default" size="100%">Human</style></keyword><keyword><style  face="normal" font="default" size="100%">Pair 1/genetics Chromosomes</style></keyword><keyword><style  face="normal" font="default" size="100%">Pair 11/genetics Chromosomes</style></keyword><keyword><style  face="normal" font="default" size="100%">Pair 3/genetics Chromosomes</style></keyword><keyword><style  face="normal" font="default" size="100%">Pair 8/genetics Female Gene Deletion Head and Neck Neoplasms/*genetics Humans Male Middle Aged Nucleic Acid Hybridization Paraganglioma/*genetics Pheochromocytoma/*genetics Tumor Markers</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2005</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=15609347</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">3</style></number><volume><style face="normal" font="default" size="100%">42</style></volume><pages><style face="normal" font="default" size="100%">260-8</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Although the histologic distinction between pheochromocytomas and head and neck paragangliomas is clear, little is known about the genetic differences between them. To date, various sets of genes have been found to be involved in inherited susceptibility to developing both tumor types, but the genes involved in sporadic pathogenesis are still unknown. To define new candidate regions, we performed CGH analysis on 29 pheochromocytomas and on 24 paragangliomas mainly of head and neck origin (20 of 24), which allowed us to differentiate between the two tumor types. Loss of 3q was significantly more frequent in pheochromocytomas, and loss of 1q appeared only in paragangliomas. We also found gain of 11q13 to be a significantly frequent alteration in malignant cases of both types. In addition, recurrent loss of 8p22-23 was found in 62% of pheochromocytomas (including all malignant cases) versus in 33% of paragangliomas, suggesting that this region contains candidate genes involved in the pathogenesis of this abnormality. Using FISH analysis on tissue microarrays, we confirmed genomic deletion of this region in 55% of pheochromocytomas compared to 12% of paragangliomas. Loss of 8p22-23 appears to be an important event in the sporadic development of these tumors, and additional molecular studies are necessary to identify candidate genes in this chromosomal region.</style></abstract><notes><style face="normal" font="default" size="100%">Cascon, Alberto Ruiz-Llorente, Sergio Rodriguez-Perales, Sandra Honrado, Emiliano Martinez-Ramirez, Angel Leton, Rocio Montero-Conde, Cristina Benitez, Javier Dopazo, Joaquin Cigudosa, Juan C Robledo, Mercedes Research Support, Non-U.S. Gov’t United States Genes, chromosomes &amp; cancer Genes Chromosomes Cancer. 2005 Mar;42(3):260-8.</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Palacios, J.</style></author><author><style face="normal" font="default" size="100%">Honrado, E.</style></author><author><style face="normal" font="default" size="100%">Osorio, A.</style></author><author><style face="normal" font="default" size="100%">Cazorla, A.</style></author><author><style face="normal" font="default" size="100%">Sarrio, D.</style></author><author><style face="normal" font="default" size="100%">Barroso, A.</style></author><author><style face="normal" font="default" size="100%">Rodriguez, S.</style></author><author><style face="normal" font="default" size="100%">Cigudosa, J. C.</style></author><author><style face="normal" font="default" size="100%">Diez, O.</style></author><author><style face="normal" font="default" size="100%">Alonso, C.</style></author><author><style face="normal" font="default" size="100%">Lerma, E.</style></author><author><style face="normal" font="default" size="100%">Dopazo, J.</style></author><author><style face="normal" font="default" size="100%">Rivas, C.</style></author><author><style face="normal" font="default" size="100%">Benitez, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers</style></title><secondary-title><style face="normal" font="default" size="100%">Breast Cancer Res Treat</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adult Apoptosis Breast Neoplasms/*genetics/*pathology Cell Cycle Proteins Cluster Analysis Female *Genes</style></keyword><keyword><style  face="normal" font="default" size="100%">Biological/genetics/metabolism</style></keyword><keyword><style  face="normal" font="default" size="100%">BRCA1 *Genes</style></keyword><keyword><style  face="normal" font="default" size="100%">BRCA2 Humans Immunohistochemistry In Situ Hybridization</style></keyword><keyword><style  face="normal" font="default" size="100%">Fluorescence Phenotype Spain *Tissue Array Analysis *Tumor Markers</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2005</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=15770521</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">1</style></number><volume><style face="normal" font="default" size="100%">90</style></volume><pages><style face="normal" font="default" size="100%">5-14</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Familial breast cancers that are associated with BRCA1 or BRCA2 germline mutations differ in both their morphological and immunohistochemical characteristics. To further characterize the molecular difference between genotypes, the authors evaluated the expression of 37 immunohistochemical markers in a tissue microarray (TMA) containing cores from 20 BRCA1, 14 BRCA2, and 59 sporadic age-matched breast carcinomas. Markers analyzed included, amog others, common markers in breast cancer, such as hormone receptors, p53 and HER2, along with 15 molecules involved in cell cycle regulation, such as cyclins, cyclin dependent kinases (CDK) and CDK inhibitors (CDKI), apoptosis markers, such as BCL2 and active caspase 3, and two basal/myoepithelial markers (CK 5/6 and P-cadherin). In addition, we analyzed the amplification of CCND1, CCNE, HER2 and MYC by FISH.Unsupervised cluster data analysis of both hereditary and sporadic cases using the complete set of immunohistochemical markers demonstrated that most BRCA1-associated carcinomas grouped in a branch of ER-, HER2-negative tumors that expressed basal cell markers and/or p53 and had higher expression of activated caspase 3. The cell cycle proteins associated with these tumors were E2F6, cyclins A, B1 and E, SKP2 and Topo IIalpha. In contrast, most BRCA2-associated carcinomas grouped in a branch composed by ER/PR/BCL2-positive tumors with a higher expression of the cell cycle proteins cyclin D1, cyclin D3, p27, p16, p21, CDK4, CDK2 and CDK1. In conclusion, our study in hereditary breast cancer tumors analyzing 37 immunohistochemical markers, define the molecular differences between BRCA1 and BRCA2 tumors with respect to hormonal receptors, cell cycle, apoptosis and basal cell markers.</style></abstract><notes><style face="normal" font="default" size="100%">Palacios, Jose Honrado, Emiliano Osorio, Ana Cazorla, Alicia Sarrio, David Barroso, Alicia Rodriguez, Sandra Cigudosa, Juan C Diez, Orland Alonso, Carmen Lerma, Enrique Dopazo, Joaquin Rivas, Carmen Benitez, Javier Research Support, Non-U.S. Gov’t Netherlands Breast cancer research and treatment Breast Cancer Res Treat. 2005 Mar;90(1):5-14.</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alvarez, S.</style></author><author><style face="normal" font="default" size="100%">Diaz-Uriarte, R.</style></author><author><style face="normal" font="default" size="100%">Osorio, A.</style></author><author><style face="normal" font="default" size="100%">Barroso, A.</style></author><author><style face="normal" font="default" size="100%">Melchor, L.</style></author><author><style face="normal" font="default" size="100%">Paz, M. F.</style></author><author><style face="normal" font="default" size="100%">Honrado, E.</style></author><author><style face="normal" font="default" size="100%">Rodriguez, R.</style></author><author><style face="normal" font="default" size="100%">Urioste, M.</style></author><author><style face="normal" font="default" size="100%">Valle, L.</style></author><author><style face="normal" font="default" size="100%">Diez, O.</style></author><author><style face="normal" font="default" size="100%">Cigudosa, J. C.</style></author><author><style face="normal" font="default" size="100%">Dopazo, J.</style></author><author><style face="normal" font="default" size="100%">Esteller, M.</style></author><author><style face="normal" font="default" size="100%">Benitez, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A predictor based on the somatic genomic changes of the BRCA1/BRCA2 breast cancer tumors identifies the non-BRCA1/BRCA2 tumors with BRCA1 promoter hypermethylation</style></title><secondary-title><style face="normal" font="default" size="100%">Clin Cancer Res</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">BRCA1 Protein/*genetics BRCA2 Protein/*genetics Breast Neoplasms/*genetics/pathology Chromosomes</style></keyword><keyword><style  face="normal" font="default" size="100%">Genetic/*genetics</style></keyword><keyword><style  face="normal" font="default" size="100%">Human</style></keyword><keyword><style  face="normal" font="default" size="100%">Human Humans Male Mutation Nucleic Acid Hybridization/methods Promoter Regions</style></keyword><keyword><style  face="normal" font="default" size="100%">Pair 12/genetics Chromosomes</style></keyword><keyword><style  face="normal" font="default" size="100%">Pair 15/genetics Chromosomes</style></keyword><keyword><style  face="normal" font="default" size="100%">Pair 18/genetics Chromosomes</style></keyword><keyword><style  face="normal" font="default" size="100%">Pair 2/genetics Chromosomes</style></keyword><keyword><style  face="normal" font="default" size="100%">Pair 8/genetics *DNA Methylation Female Genome</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2005</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=15709182</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">3</style></number><volume><style face="normal" font="default" size="100%">11</style></volume><pages><style face="normal" font="default" size="100%">1146-53</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">The genetic changes underlying in the development and progression of familial breast cancer are poorly understood. To identify a somatic genetic signature of tumor progression for each familial group, BRCA1, BRCA2, and non-BRCA1/BRCA2 (BRCAX) tumors, by high-resolution comparative genomic hybridization, we have analyzed 77 tumors previously characterized for BRCA1 and BRCA2 germ line mutations. Based on a combination of the somatic genetic changes observed at the six most different chromosomal regions and the status of the estrogen receptor, we developed using random forests a molecular classifier, which assigns to a given tumor a probability to belong either to the BRCA1 or to the BRCA2 class. Because 76.5% (26 of 34) of the BRCAX cases were classified with our predictor to the BRCA1 class with a probability of &gt;50%, we analyzed the BRCA1 promoter region for aberrant methylation in all the BRCAX cases. We found that 15 of the 34 BRCAX analyzed tumors had hypermethylation of the BRCA1 gene. When we considered the predictor, we observed that all the cases with this epigenetic event were assigned to the BRCA1 class with a probability of &gt;50%. Interestingly, 84.6% of the cases (11 of 13) assigned to the BRCA1 class with a probability &gt;80% had an aberrant methylation of the BRCA1 promoter. This fact suggests that somatic BRCA1 inactivation could modify the profile of tumor progression in most of the BRCAX cases.</style></abstract><notes><style face="normal" font="default" size="100%">Alvarez, Sara Diaz-Uriarte, Ramon Osorio, Ana Barroso, Alicia Melchor, Lorenzo Paz, Maria Fe Honrado, Emiliano Rodriguez, Raquel Urioste, Miguel Valle, Laura Diez, Orland Cigudosa, Juan Cruz Dopazo, Joaquin Esteller, Manel Benitez, Javier Comparative Study Research Support, Non-U.S. Gov’t United States Clinical cancer research : an official journal of the American Association for Cancer Research Clin Cancer Res. 2005 Feb 1;11(3):1146-53.</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Melendez, B.</style></author><author><style face="normal" font="default" size="100%">Diaz-Uriarte, R.</style></author><author><style face="normal" font="default" size="100%">Cuadros, M.</style></author><author><style face="normal" font="default" size="100%">Martinez-Ramirez, A.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Piqueras, J.</style></author><author><style face="normal" font="default" size="100%">Dopazo, A.</style></author><author><style face="normal" font="default" size="100%">Cigudosa, J. C.</style></author><author><style face="normal" font="default" size="100%">Rivas, C.</style></author><author><style face="normal" font="default" size="100%">Dopazo, J.</style></author><author><style face="normal" font="default" size="100%">Martinez-Delgado, B.</style></author><author><style face="normal" font="default" size="100%">Benitez, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Gene expression analysis of chromosomal regions with gain or loss of genetic material detected by comparative genomic hybridization</style></title><secondary-title><style face="normal" font="default" size="100%">Genes Chromosomes Cancer</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Chromosomes</style></keyword><keyword><style  face="normal" font="default" size="100%">Fluorescence Lymphoma</style></keyword><keyword><style  face="normal" font="default" size="100%">Human</style></keyword><keyword><style  face="normal" font="default" size="100%">Pair 13/*genetics Chromosomes</style></keyword><keyword><style  face="normal" font="default" size="100%">Pair 19/*genetics Chromosomes</style></keyword><keyword><style  face="normal" font="default" size="100%">Pair 6/*genetics Expressed Sequence Tags *Gene Dosage Gene Expression Profiling Humans In Situ Hybridization</style></keyword><keyword><style  face="normal" font="default" size="100%">T-Cell/*genetics Nucleic Acid Hybridization Oligonucleotide Array Sequence Analysis</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2004</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=15382261</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">4</style></number><volume><style face="normal" font="default" size="100%">41</style></volume><pages><style face="normal" font="default" size="100%">353-65</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Comparative genomic hybridization (CGH) has been widely used to detect copy number alterations in cancer and to identify regions containing candidate tumor-responsible genes; however, gene expression changes have been described only in highly amplified regions (amplicons). To study the overall impact of slight copy number changes on gene expression, we analyzed 16 T-cell lymphomas by using CGH and a custom-designed cDNA microarray containing 7,657 genes and expressed sequence tags related to tumorigenesis. We evaluated mean gene expression and variability within CGH-altered regions and explored the relationship between the effects of the gene and its position within these regions. Minimally overlapping CGH candidate areas (6q25, 13q21-q22, and 19q13.1) revealed a weak relationship between altered genomic content and gene expression. However, some candidate genes showed modified expression within these regions in the majority of tumors; these candidate genes were evaluated and confirmed in another independent series of 23 T-cell lymphomas by use of the same cDNA microarray and by FISH on a tissue microarray. When all the CGH regions detected for each tumor were considered, we found a significant increase or decrease in the mean expression of the genes contained in gained or lost regions, respectively. In addition, we found that the expression of a gene was dependent not only on its position within an altered region but also on its own mechanism of regulation: genes in the same altered region responded very differently to the gain or loss of genetic material. Supplementary material for this article can be found on the Genes, Chromosomes, and Cancer website at http://www.interscience.wiley.com/jpages/1045-2257/suppmat/index.html.</style></abstract><notes><style face="normal" font="default" size="100%">Melendez, Barbara Diaz-Uriarte, Ramon Cuadros, Marta Martinez-Ramirez, Angel Fernandez-Piqueras, Jose Dopazo, Ana Cigudosa, Juan-Cruz Rivas, Carmen Dopazo, Joaquin Martinez-Delgado, Beatriz Benitez, Javier Research Support, Non-U.S. Gov’t United States Genes, chromosomes &amp; cancer Genes Chromosomes Cancer. 2004 Dec;41(4):353-65.</style></notes></record></records></xml>